Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 4/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5513864 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL12868799 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL15592462 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL10136513 | 1.00 | SLC1A2 (0.42) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL11295143 | 0.98 | SLC1A2 (0.41) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL10289797 | 0.95 | ACE (0.44) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL14473782 | 0.95 | ACE (0.44) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL14072902 | 0.95 | ACE (0.44) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL17628741 | 0.95 | ACE (0.44) | SLC1A2SLC1A1EPHX1ACEKDM4E | |
| SCHEMBL14072906 | 0.95 | ACE (0.44) | SLC1A2SLC1A1EPHX1ACEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | SLC1A2 1981/4885SLC1A1 795/4885EPHX1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.